Reliable medicine information should be based on authoritative medical and regulatory sources. Enzalutamide40mg.com uses regulatory and official product information as important reference material for educational content.
European Medicines Agency — Xtandi
The European Medicines Agency provides official information for Xtandi, a medicine containing enzalutamide.
The EMA information describes approved uses in specified prostate cancer settings, including metastatic hormone-sensitive prostate cancer, metastatic castration-resistant prostate cancer, high-risk non-metastatic castration-resistant prostate cancer, and certain high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer settings.
European Medicines Agency — Product Information
The EMA product information provides detailed regulatory information concerning the composition, available tablet strengths, recommended administration, precautions, adverse reactions, and other prescribing considerations for Xtandi.
The current European product information identifies 40 mg and 80 mg film-coated tablets and describes a recommended adult dose of 160 mg once daily for the approved product.
European Medicines Agency — Enzalutamide Generic Information
The EMA also provides information concerning authorized enzalutamide generic products. Such information is useful for understanding the relationship between the generic active ingredient and reference medicines.
One EMA-listed enzalutamide medicine is described as a generic containing enzalutamide with Xtandi as the reference medicine.
How to Use These References
Readers should give priority to official regulatory documentation applicable to the country in which treatment is being prescribed or dispensed.
Useful sources may include:
- National medicines regulatory agencies
- Official product labels
- Approved patient information leaflets
- Regulatory assessment reports
- Hospital or oncology treatment protocols
- Qualified healthcare professionals
Why Regulatory Sources Matter
Prescription medicines can have different approved indications, formulations, warnings, and labeling requirements in different jurisdictions.
For this reason, an educational website should not assume that information approved in one country automatically applies everywhere.
The EMA information, for example, describes specific European regulatory indications for Xtandi.
Medical Literature
Scientific publications and clinical guidelines can provide additional information about enzalutamide, including its pharmacology, clinical trials, treatment combinations, and outcomes.
However, individual medical papers should be interpreted within their study design and publication context. A clinical trial result does not automatically mean that every patient is an appropriate candidate for the treatment.
Reference Use on This Website
The references support educational explanations of:
- What enzalutamide is
- Its mechanism of action
- Prostate cancer treatment settings
- General administration
- Important safety information
- Known adverse reactions
- Product strengths
- Regulatory terminology
- Product verification principles
They do not replace the official prescribing information for a patient’s specific medicine.
Keeping Information Current
Regulatory information can change.
Patients and healthcare professionals should therefore consult current official documentation rather than relying exclusively on archived website material.
If there is a conflict between this website and the official prescribing information supplied with a medicine, the official current prescribing information should take precedence.
Reference Transparency
Enzalutamide40mg.com is intended to present medical information in a transparent, educational manner. The website should distinguish between:
- Generic medicine information
- Product-specific information
- Regulatory information
- General educational explanations
- Individual medical advice
The site does not intend to imply that every product, strength, indication, or manufacturer arrangement is authorized in every country.